Page 5 - Multiple Ascending Dose News Today

Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

-- Company to host key opinion leader webinar today, October 1, at 10:00am ET --LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing

Investegate announcements from Amolyt Pharma, Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results May 10, 2021 16:05 ET | Source: Larimar Therapeutics Larimar Therapeutics Bala Cynwyd, UNITED STATES - Topline data from placebo-controlled Phase 1 program in Friedreichs ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa....

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology ASLAN PHARMACEUTICALS LIMITEDMay 5, 2021 GMT - ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021 SINGAPORE, May 05, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage immunology focused b...